For breast cancer survivors, the words “you’re done with treatment” don’t always mean the end of worry. Recurrence is a real and valid concern—and the tools available to monitor it are evolving rapidly. That’s why at Learn Look Locate, we’re highlighting one of the most advanced options available today: Signatera™, a personalized circulating tumor DNA (ctDNA) test developed by Natera.
This blog supports our ongoing mission to help breast cancer patients better understand recurrence risk, early detection strategies, and how to take empowered steps forward check out
Breast Cancer Recurrence and ctDNA: Featuring Dr. Barry Rosen
Unlike other ctDNA tests, Signatera™ is custom-built for each individual patient. Using a sample from the original tumor, it identifies your personal set of genetic mutations—like a fingerprint—and then watches for those specific DNA fragments in your bloodstream.
Key Advantages:
As a breast cancer survivor, I know how terrifying it can be to finish treatment and still feel unsure about what’s next. That’s why I sat down with Dr. Barry Rosen, a trusted Breast Surgical Oncologist and Senior Medical Advisor for Learn Look Locate, to ask the questions so many of us carry—but rarely say out loud.
In our exclusive interview, Dr. Rosen breaks down what makes Signatera™ different, how it works, and what it means for patients like you and me who just want peace of mind and a way to stay informed.
Whether you’re just finishing treatment or years into survivorship, this is a conversation you don’t want to miss. It’s patient-focused, clear, and packed with answers to the exact things we worry about.
What exactly is ctDNA?
ctDNA stands for circulating tumor DNA—fragments of DNA from cancer cells that are shed into the bloodstream. Detecting ctDNA can signal the presence of residual or returning cancer.
How often should Signatera™ be used?
It can be used periodically after treatment to monitor for recurrence. Your doctor will guide the ideal frequency based on your diagnosis and stage.
Does a positive Signatera™ result mean my cancer is back?
Not necessarily. A positive result shows ctDNA in your blood, which may indicate early signs of recurrence. Your care team may follow up with more imaging or tests.
Is Signatera™ covered by insurance?
Yes. It’s covered by Medicare for eligible patients with stage IIb or higher breast cancer. Private insurance coverage may vary.
Should I ask my oncologist about it?
Absolutely. Signatera™ offers a personalized monitoring option that could be the right fit for you—especially if you’re concerned about recurrence.
This blog is proudly sponsored by Natera. Signatera™ offers cutting-edge, personalized insight into breast cancer recurrence—empowering patients and physicians to make more informed decisions together.
Learn Look Locate is here for you. We know how overwhelming it can feel to search for answers—especially when you’re trying to find the latest treatments, understand new options, or even figure out the right questions to ask. That’s why we created this space. We want everything in one place. We want you to feel seen, supported, and empowered.
It shouldn’t be this hard to find what could help you.
We’re working every day to bring forward the most current and credible information—directly from trusted medical experts—and present it in a way that actually makes sense. So if you’re feeling unsure about what’s next, know this: you’re not alone. And you don’t have to do this alone.
We’re learning together. And we’re not stopping.
Share This Story, Choose Your Platform!
Address: 5800 W. Arizona Pavilions Dr. Suite 1816
Cortaro, Arizona 85652